Program
FRIDAY, OCTOBER 16, 2020
Saturday, October 17, 2020
- Plenary Session 1: Synthetic Biology and Novel Approaches to Immune Engineering
- Plenary Session 2: Vaccines, Neoantigens, and Oncolytic Viruses
- Networking Event
- Keynote Presentation
Sunday, October 18, 2020
- Plenary Session 3: T-Cell Therapies
- Plenary Session 4: Non-T-Cell Therapies
- Plenary Session 5: Novel Combinations
Monday, October 19, 2020
- Plenary Session 6: Innate and Adaptive Checkpoints
- Plenary Session 7: Defining Novel Immunotherapy Targets
FRIDAY, OCTOBER 16, 2020
OPENING REMARKS AND OPENING KEYNOTES
5-7 P.M.
A case for priming, not checkpoint
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Clinical development of BCMA-directed therapies in multiple myeloma
Kristen M. Hege, Celgene Corporation, San Francisco, California
Opening Reception
7-9 P.M.
Saturday, October 17, 2020
Continental Breakfast
7-8 A.M.
Plenary Session 1: Synthetic Biology and Novel Approaches to Immune Engineering
8-10 A.M.
Engineering artificial Antigen Presenting Complexes, aAPC, for cancer immunotherapy: From bench to bedside
Jonathan P. Schneck, Johns Hopkins University School of Medicine, Baltimore, Maryland
Title to be announced
Pamela A. Silver, Harvard Medical School, Boston, Massachusetts
Additional speaker to be announced
Break
10-10:30 A.M.
Plenary Session 2: Vaccines, Neoantigens, and Oncolytic Viruses
10:30 A.M.-12:30 P.M.
Building improved personal cancer vaccines
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
Title to be announced
Adrian Hill, Jenner Institute at Oxford University, Oxford, England
Additional speaker to be announced
Poster Session A/Lunch
12:30-3 P.M.
Networking Event
3-4 P.M.
Timothy A. Chan, Memorial Sloan Kettering Cancer Center, New York, New York
Keynote Presentation
4-5 P.M.
Speaker to be announced
Evening on own
5 P.M.
Sunday, October 18, 2020
Continental Breakfast
7-8 A.M.
Plenary Session 3: T-Cell Therapies
8-10 A.M.
Title to be announced
Marcela V. Maus, Massachusetts General Hospital, Boston, Massachusetts
Title to be announced
Avery D. Posey, University of Pennsylvania, Philadelphia, Pennsylvania
CARs and armoured CARs
Renier J. Brentjens, Memorial Sloan Kettering Cancer Institute, New York, New York
Break
10-10:30 A.M.
Plenary Session 4: Non-T-Cell Therapies
10:30 A.M.-12:30 P.M.
Title to be announced
Adrian C. Hayday, The Francis Crick Institute, London, England
Title to be announced
Judith Agudo, Dana-Farber Cancer Institute, Boston, Massachusetts
Title to be announced
Elizabeth J. Shpall, MD Anderson Cancer Center, Houston, Texas
Lunch on Own
12:30-2:30 P.M.
Plenary Session 5: Novel Combinations
2:30-4:30 P.M.
Title to be announced
Charles G. Drake, Columbia University Irving Medical Center, New York, New York
The QuEST for an effective immunotherapy for prostate cancer
James L. Gulley, National Cancer Institute, Bethesda, Maryland
Additional speaker to be announced
Poster Session B/Reception
4:30-7 P.M.
Monday, October 19, 2020
Continental Breakfast
7-8 A.M.
Plenary Session 6: Innate and Adaptive Checkpoints
8-10 A.M.
Targeting macrophages to promote anti-tumor immunity
Judith A. Varner, UCSD Moores Cancer Center, San Diego, California
Innate immune defenses against cancer: Potential for mobilizing NK cells for cancer immunotherapy
David H. Raulet, University of California, Berkeley, Berkeley, California
Additional speaker to be announced
Break
10-10:30 A.M.
Plenary Session 7: Defining Novel Immunotherapy Targets
10:30 A.M.-12:30 P.M.
Probing the immune system in cancer
Stephen J. Elledge, Harvard Medical School, Boston, Massachusetts
Title to be announced
Arlene H. Sharpe, Harvard Medical School, Boston, Massachusetts
Title to be announced
Peter A. Sims, Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York